Argent Biopharma
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 19 Aug 2024
- Reported shorts
- 1
- Shares on issue
- 48.406M
Argent Biopharma (RGT) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency · Company filing, 31 Aug 2026
- Revenue
- $161.2KM (source: ASX (Markit))vs $583.4K (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$7.7MM (source: ASX (Markit))vs −$17.8M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (basic)
- −$0.089F (source: Company filing (extracted))vs −$0.31 (FY25)
- Company filing (extracted), as at 14 Oct 2026
- Rev YoY
- −72.4%FY
- EPS YoY
- n/aFY
- ASX (Markit)
- Company filing (extracted)
Summary of Appendix 4E and 2026 Annual Report, 31 Aug 2026
Argent BioPharma reported revenue of $161,187 for FY2026, down 11% from the prior year, while net loss narrowed significantly by 57% to $7.7 million, reflecting improved cost discipline. No dividend was declared. The company highlighted a post-period licensing deal for CannEpil® that eliminates its principal secured debt and retains a 15% royalty, positioning it for long-term growth.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- −4,783.3%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $161.2KM (source: ASX (Markit)) | $583.4K | $891.1K | $3.4M |
| Gross profit | n/a | $446.3K | $203.7K | $1.5M |
| Operating income | n/a | −$15.4M | −$18.3M | −$15.6M |
| EBITDA | n/a | −$17.0M | −$15.8M | −$20.0M |
| EBIT | n/a | −$17.8M | −$17.1M | −$20.8M |
| Interest expense | n/a | $51.3K | $482.5K | $337.0K |
| Pretax income | n/a | −$17.8M | −$17.5M | −$21.1M |
| Tax | n/a | $0 | $0 | $2.0K |
| NPAT | −$7.7MM (source: ASX (Markit)) | −$17.8M | −$17.5M | −$20.8M |
| Net interest income | n/a | −$49.1K | −$480.5K | −$336.8K |
| EPS basic | −$0.089F (source: Company filing (extracted)) | −$0.31 | −$0.47 | −$7.10 |
| EPS diluted | n/a | −$0.31 | −$0.47 | −$7.10 |
| Shares | n/a | 72.2M | 45.3M | 3.4M |
- ASX (Markit)
- Company filing (extracted)
Financial reports
The company's own filings, newest first
- Appendix 4E and 2026 Annual ReportAnnual Results31 Aug 2026via asx_announcements
Figures above come from this filing
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results27 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E and 2025 Annual ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
- Half Year AccountsHalf Year Results28 Feb 2025via asx_announcements
Showing 10 of 84 reports